Nifedipin Stada (Nifedipine)

• Nifedipine is indicated for conditions involving vascular tone and myocardial oxygen demand.
• Hypertension: reduces systemic vascular resistance, leading to lower blood pressure.
• Chronic stable angina: improves coronary blood flow, decreasing frequency of angina attacks.
• Raynaud's phenomenon: alleviates vasospasm in peripheral arteries, reducing episodes of color change and pain.

• Nifedipine selectively blocks L‑type calcium channels in vascular smooth muscle and cardiac myocytes. By inhibiting calcium influx, it prevents contraction of arterial smooth muscle, causing vasodilation of peripheral and coronary vessels. The resulting decrease in peripheral resistance lowers blood pressure, while enhanced coronary blood flow improves myocardial oxygen delivery. Its dihydropyridine structure confers greater vascular selectivity compared with non‑dihydropyridine calcium antagonists.

Nifedipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate headache often occurring after the first dose.
• Flushing: sensation of warmth and redness, especially on the face and neck.
• Peripheral edema: swelling of ankles or lower legs due to fluid accumulation.
• Dizziness: light‑headedness related to blood pressure reduction.
• Tachycardia: compensatory increase in heart rate.
• Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease.
• Allergic reactions: rash, itching, or anaphylaxis requiring immediate medical attention.
• Liver dysfunction: elevated liver enzymes or hepatitis.
• Heart block: abnormal conduction leading to bradyarrhythmias.

• When prescribing Nifedipine, clinicians should consider several safety precautions to minimize risk.
• Monitor blood pressure: regularly assess to ensure therapeutic response and avoid excessive hypotension.
• Avoid abrupt discontinuation: tapering is recommended to prevent rebound hypertension.
• Use caution in hepatic impairment: dose adjustment may be required due to metabolism in the liver.
• Use caution in heart failure: monitor for worsening symptoms as vasodilation can affect preload.
• Avoid concomitant grapefruit juice: it can increase plasma concentrations of nifedipine.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nifedipine interacts with several medicines; understanding the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase nifedipine levels, raising risk of severe hypotension.
• Nitrates (e.g., nitroglycerin): combined vasodilatory effect may cause dangerous blood pressure drops.
• Other calcium channel blockers (e.g., verapamil): additive cardiovascular depression.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt compensatory tachycardia, requiring blood pressure monitoring.
• Diuretics: enhanced antihypertensive effect may lead to excessive volume depletion.
• Digoxin: increased serum digoxin concentrations have been reported.
• Simvastatin: CYP3A4 competition may raise statin levels, increasing risk of myopathy.
• Antacids (aluminum or magnesium): may reduce absorption of nifedipine, affecting efficacy.